| HC stops Zydus drug sale on Sun petition | 11-NOV-09 |
|
| The Madras High Court today directed Ahmedabad-based Zydus Cadila (Cadila Healthcare) not to sell its anti-depressant drug, Venz (venlafaxine), in the domestic market for the time being, based on a trademark complaint from Mumbai-based Sun Pharmaceutical industries. |
|
|
|
| Latha Jishnu: The campaign against that pesky 3 (d) | 14-OCT-09 |
|
| For the Americans (and some Europeans) it’s “that pesky section”. And the US government is throwing its weight behind an industry campaign to discredit this section if not get it removed from India’s Patent Act. Yes, of course, it is Section 3(d) that is under attack from big pharma which has lost no opportunity in pointing out that this law will stifle the growth of India’s own drug companies and also choke off foreign investment in the sector. In recent weeks, this campaign has picked up in tempo both here and abroad. |
|
|
|
|
|
|
| Novartis moves SC against Glivec order | 29-AUG-09 |
|
| Swiss drug major Novartis has approached the Supreme Court against a decision of the country’s apex patent complaint redressal forum, the Intellectual Property Appellate Board (IPAB), to deny patent protection for its cancer medicine, Glivec. |
|
|
|
|
|
|
| Novartis loses battle for cancer drug patent | 05-JUL-09 |
|
| Novartis’s famed cancer drug, Glivec, will not get patent protection in India. The apex body on patent and trademark disputes, the Intellectual Property Appellate Board (IPAB), has ruled that the drug “lacks innovation” and the high price tag of Rs 1,20,000 per month per patient would be too high for the common man. “Any patent granted to support such a high monopoly price would be against ‘public order’,” the ruling said. |
|
|
|
| Glivec final hearing from Nov 17 | 05-NOV-08 |
|
| The high profile legal battle over patent rights of Glivec, a blockbuster cancer drug from the stables of Swiss pharma major Novartis, will enter its final phase on November 17.
The Intellectual |
|
|
|
| Apex court wants expert member on patent board | 04-SEP-08 |
|
| The Supreme Court on Tuesday suggested that the Centre should consider having an expert member on the Intellectual Property Appellate Board (IPAB) that reviews decisions of the Indian patent |
|
|
|
| Perfetti bursts Candico `Big Bubble`, legally | 10-JAN-08 |
|
| Italian candy maker Perfetti Van Melle SPA has won a nine-year old trademark battle before the Intellectual Property Appellate Board (IPAB), which has dismissed Nagpur-based confectioner Candicos |
|
|
|
| Novartis case hearing adjourned to Nov 6 | 24-OCT-07 |
|
| The Madras High Court has adjourned the hearing on the Novartis patent case to November 6 after the Hyderabad-based Natco Pharma raised objections against the Union governments proposal of excluding |
|
|
|
| Novartis loses plea on patent board member | 21-JUL-07 |
|
| The Intellectual Property Appellate Board (IPAB) today dismissed Novartiss petition seeking a new member in place of former Patent Controller S Chandrasekhar to hear its appeal on the denial of an |
|
|
|
| Patent board reserves verdict on Novartis plea | 11-JUL-07 |
|
| The Indian Patent Appellate Board (IPAB) on Tuesday reserved judgement on Novartis appeal challenging the appointment of former Controller General of Patents S Chandrasekhar as a technical member of |
|
|
|
| Novartis objects to IPAB appointment | 19-JUN-07 |
|
| Swiss drug-maker Novartis today objected to the appointment of S Chandrasekhar, the former Controller General of Patents, as a technical member of the Intellectual Property Appellate Board (IPAB), |
|
|
|
| Patents offices need to gear up | 29-NOV-04 |
|
| The Ordinance introducing the product patents regime in pharmaceuticals, agro-chemicals and food is in place, but India needs to do much more to equip its patents offices to handle the rush of |
|
|
|
|
|
|
Content Guide
